Industry: Pharmaceuticals, Biotechnology
Portola Pharmaceuticals, Inc. is a private biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapeutics for acute and chronic cardiovascular and vascular disease. Portola has two drug candidates in clinical development. The most advanced compound is an oral Factor Xa inhibitor that is entering a Phase II trial for the prevention of DVT in patients undergoing knee surgery. Following closely behind is a direct acting, orally available ADP (P2Y12) receptor antagonist in multiple Phase I trials. Both of these drug candidates bring significant potential advances to the $14 billion anti-thrombotics ( www.portola.com )
Portola Pharmaceuticals , Inc.
270 E. Grand Avenue Suite 22
South San Francisco, California 94080
USA
Tel: (650) 246-7000
Fax: (650) 246-7776